SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has advanced its lead drug candidate GEP-44 into an IND-enabling preclinical program, marking a key step toward first-in-human clinical trials. The company announced the initiation of a Good Laboratory Practice (GLP) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (FDA) requirements, designed to support an Investigational New Drug (IND) application. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, with preclinical results positioning GEP-44 head-to-head with established therapies such as Ozempic, Mounjaro, and Wegovy.
GEP-44 is a multi-receptor peptide targeting obesity and type 2 diabetes, developed as a next-generation incretin-based therapy. SureNano secured licensing rights to the compound from Syracuse University and has since positioned it within the booming GLP-1 market. The global GLP-1 receptor agonist market projections range widely, with estimates from $100 billion to J.P. Morgan's forecast of $200 billion by 2030. In the United States alone, approximately 25 million patients are expected to use GLP-1 therapies by 2030, underscoring the massive addressable market.
The company’s transition toward a pharmaceutical-focused model follows its acquisition of GlucaPharm, which now operates in this rapidly expanding sector. SureNano is positioning itself as an agile entrant among larger competitors, aiming to capture market share with a patented, high-performing second-generation therapy. The IND-enabling program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
Beyond GEP-44, SureNano is also exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments. This diversification strategy could broaden the company's pipeline and address other significant health challenges.
The implications for the industry are substantial. If GEP-44 successfully completes clinical trials, it could offer a new treatment option in the obesity and diabetes space, potentially providing improved efficacy or tolerability compared to existing drugs. For patients, this could mean more choices and possibly better outcomes in managing chronic conditions that affect millions worldwide. For SureNano, success could translate into significant revenue in a market projected to reach $200 billion by 2030, establishing the company as a notable player in the pharmaceutical landscape.
However, the path to market is fraught with risks, including trial outcomes, regulatory hurdles, and the need for continued capital. The company acknowledges that forward-looking information involves risks and uncertainties, and actual results might differ materially from projections. Investors are encouraged to review the full disclaimers and forward-looking statements available in the company's newsroom.
